• Disease
  • Parkinsons
  • Parkinsons Disease
  • Andrew John Andrew

    Prominent publications by Andrew John Andrew

    KOL Index score: 17572

    BACKGROUND: Opicapone is a novel, once-daily, potent third-generation catechol-O-methyltransferase inhibitor. We aimed to assess the safety and efficacy of opicapone as an adjunct to levodopa compared with placebo or entacapone in patients with Parkinson's disease and motor fluctuations.

    METHODS: We did a randomised, double-blind, placebo-controlled and active-controlled trial of opicapone as an adjunct to levodopa in patients with Parkinson's disease with end-of-dose motor fluctuations. ...

    Also Ranks for: Placebo Patients |  opicapone 50 |  motor fluctuations |  parkinsons disease |  levodopa treatment
    KOL Index score: 16976

    The aim of the study was to evaluate the frequency and to perform phenotypic and genotypic characterization of familial Parkinsonism and early onset Parkinson's disease (EOPD) in a Brazilian movement disorder unit. We performed a standardized clinical assessment of patients followed by sequencing of PRKN, PINK1 in EOPD cases and SNCA, LRRK2 in familial Parkinsonism individuals. During the period of study (January through December, 2006), we examined 575 consecutive patients of whom 226 ...

    Also Ranks for: Early Onset |  lrrk2 mutations |  prkn pink1 |  parkinsons disease |  eopd age
    KOL Index score: 16777

    The rate of brain atrophy and its relationship to clinical disease progression in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) is not clear. Twenty-four patients with PSP, 11 with MSA-P (Parkinsonian variant), 12 with Parkinson's disease, and 18 healthy control subjects were recruited for serial MRI scans, clinical assessments and formal neuropsychological evaluations in order to measure brain atrophy during life and its association with disease progression in ...

    Also Ranks for: Atrophy Rates |  supranuclear palsy |  longitudinal mri |  psp msap |  parkinsons disease
    KOL Index score: 16361

    Repetitive finger tapping is commonly used to assess bradykinesia in Parkinson's disease. The Queen Square Brain Bank diagnostic criterion of Parkinson's disease defines bradykinesia as 'slowness of initiation with progressive reduction in speed and amplitude of repetitive action'. Although progressive supranuclear palsy is considered an atypical parkinsonian syndrome, it is not known whether patients with progressive supranuclear palsy have criteria-defined bradykinesia. This study ...

    Also Ranks for: Progressive Supranuclear |  parkinsons disease |  speed amplitude |  handwriting patients |  bradykinesia slowness
    KOL Index score: 14987

    Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are neurodegenerative disorders, each with a prevalence of around 5 per 100,000. Regional brain atrophy patterns differ in the two disorders, however, and magnetic resonance imaging is sometimes helpful in distinguishing them in the later stages. We measured whole brain and regional volumes, including cerebellum, pons, midbrain, superior cerebellar peduncle (SCP), and ventricular volumes as well as frontal and ...

    Also Ranks for: Psp Msap |  regional brain |  atrophy msa |  motor disability |  topic supranuclear palsy
    KOL Index score: 14524

    Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes. To investigate the spectrum of clinicopathological correlations, we performed a semi-quantitative pathological analysis of 100 MSA cases with well-characterized clinical phenotypes. In 24 areas, chosen from both the striatonigral (StrN) and olivopontocerebellar (OPC) regions, the severity of neuronal cell loss ...

    Also Ranks for: Pathological Involvement |  snd opca |  ataxia msa |  cerebellar signs |  neuronal cell loss
    KOL Index score: 14504

    BACKGROUND: Mutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?

    METHODS: Researchers from 21 ...

    Also Ranks for: Mutations Lrrk2 |  national institute |  genetic penetrance |  parkinson disease |  motor symptoms
    KOL Index score: 14439

    Prognostic predictors have not been defined for progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). Subtypes of both disorders have been proposed on the basis of early clinical features. We performed a retrospective chart review to investigate the natural history of pathologically confirmed cases of PSP and MSA. Survival data and several clinically relevant milestones, namely: frequent falling, cognitive disability, unintelligible speech, severe dysphagia, dependence ...

    Also Ranks for: Msa Psp |  supranuclear palsy |  disease onset |  death patients |  unintelligible speech
    KOL Index score: 13895

    Clinical syndromes associated with progressive supranuclear palsy-tau pathology now include progressive supranuclear palsy-parkinsonism (PSP-P), in addition to classic Richardson's syndrome (RS) and pure akinesia with gait freezing (PAGF). Although pathological heterogeneity of progressive supranuclear palsy (PSP) has also been established, attempts to correlate this with clinical findings have only rarely provided conclusive results. The aim of this study was to investigate whether ...

    Also Ranks for: Tau Pathology |  supranuclear palsy |  substantia nigra |  psp pagf |  progressive syndrome
    KOL Index score: 13879

    The clinical diagnosis of progressive supranuclear palsy (PSP) relies on the identification of characteristic signs and symptoms. A proportion of pathologically diagnosed cases do not develop these classic features, prove difficult to diagnose during life and are considered as atypical PSP. The aim of this study was to examine the apparent clinical dichotomy between typical and atypical PSP, and to compare the biochemical and genetic characteristics of these groups. In 103 consecutive ...

    Also Ranks for: Clinical Phenotypes |  progressive supranuclear |  pspp cases |  palsy psp |  richardsons syndrome
    KOL Index score: 13846

    Importance: Atypical parkinsonian syndromes (APS), including progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), may be difficult to distinguish in early stages and are often misdiagnosed as Parkinson disease (PD). The diagnostic criteria for PSP have been updated to encompass a range of clinical subtypes but have not been prospectively studied.

    Objective: To define the distinguishing features of PSP and CBS subtypes and to assess their ...

    Also Ranks for: Corticobasal Syndrome |  progressive supranuclear |  psp cbs |  early diagnosis |  serum nfl
    KOL Index score: 13843

    The frontal assessment battery (FAB) is a bedside test of executive function. It takes less than 10 minutes to administer and a low score indicates executive dysfunction. To determine whether the FAB could detect the more severe subcortical dementia that is a feature of PSP and differentiate it from other bradykinetic rigid syndromes, we studied 17 patients with progressive supranuclear palsy (PSP); 11 with multiple system atrophy (MSA) and 12 with Parkinson's disease (PD). We compared ...

    Also Ranks for: Fab Scores |  psp msa |  frontal assessment battery |  executive function |  progressive supranuclear
    KOL Index score: 13754

    Equilibrium striatal: cerebellar 11C-raclopride (RAC) uptake ratios reflect the density of striatal dopamine D2 binding sites. Using positron emission tomographic scanning we have measured striatal RAC uptake in 6 untreated patients with Parkinson's disease (PD), 5 chronically treated patients with PD and a fluctuating response to L-dopa, 10 patients with striatonigral degeneration (SND), and 9 patients with progressive supranuclear palsy (PSP). Regional cerebral blood flow was ...

    Also Ranks for: Striatonigral Degeneration |  progressive supranuclear |  psp patients |  emission tomography |  fluctuating response
    KOL Index score: 13655

    Importance: Catechol O-methyltransferase (COMT) inhibitors are an established treatment for end-of-dose motor fluctuations associated with levodopa therapy in patients with Parkinson disease (PD). Current COMT inhibitors carry a high risk for toxic effects to hepatic cells or show moderate improvement. Opicapone was designed to be effective without the adverse effects.

    Objective: To evaluate the efficacy and safety of 25- and 50-mg/d dosages of opicapone compared with placebo as adjunct ...

    Also Ranks for: Motor Fluctuations |  parkinson disease |  levodopa therapy |  opicapone patients |  doubleblind phase


    Andrew John Andrew: Influence Statistics

    Sample of concepts for which Andrew John Andrew is among the top experts in the world.
    Concept World rank
    upsit40 ss16 #1
    rbd markers #1
    psp anxiety symptoms #1
    dj1 psp #1
    patients dyskinesia diaries #1
    sweating disturbances #1
    normal cognition patients #1
    rhinencephalon parkinsonian carriers #1
    bromocriptine arm #1
    pkd hm #1
    diplopia hazard ratio #1
    pathology dmx #1
    pathologically confirmed cases #1
    sialorrhea surgery #1
    dyskinesias aged #1
    uptake hmpao #1
    treatment apomorphine nodules #1
    early presentations #1
    parkinsonian voiding dysfunction #1
    cases abga #1
    ratings efficacy #1
    patients dds #1
    lbs iem #1
    attvib #1
    ht psp patients #1
    pathologically proven #1
    bodies tau #1
    psp fab #1
    groups hallucinators #1
    msa substantia nigra #1
    neuropathological picture #1
    steelerichardsonolszewski #1
    apomorphine pumps monotherapy #1
    tesofensine time #1
    smell tests #1
    apomorphine study #1
    brazilian football player #1
    g2019s cases ipd #1
    effectiveness opicapone #1
    dds patients medication #1
    smell test identification #1
    enhanced predict #1
    psp mcp #1
    pain 30 40 #1
    piribedil 95 #1
    cerebellum difference #1
    akinetic freezing #1
    asymmetrical onset #1
    impulsive compulsive behaviors #1
    parkinson chimera #1

    Key People For Parkinsons Disease

    Top KOLs in the world
    Andrew John Andrew
    parkinsons disease progressive supranuclear motor fluctuations
    Anthony Edward Lang
    parkinson disease movement disorders subthalamic nucleus
    Charles W Olanow
    parkinson disease oxidative stress motor complications
    Werner H Poewe
    parkinson disease multiple atrophy restless legs syndrome
    Christopher G Goetz
    parkinson disease movement disorders rating scales
    Joseph J Jankovic
    movement disorders parkinson disease essential tremor

    Andrew John Andrew:Expert Impact

    Concepts for whichAndrew John Andrewhas direct influence:Parkinsons disease,  Parkinson disease,  Progressive supranuclear,  Supranuclear palsy,  Motor fluctuations,  Lewy bodies,  Substantia nigra,  Multiple atrophy.

    Andrew John Andrew:KOL impact

    Concepts related to the work of other authors for whichfor which Andrew John Andrew has influence:Parkinson disease,  Lewy bodies,  Oxidative stress,  Cognitive impairment,  Substantia nigra,  Movement disorders,  Dopaminergic neurons.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Reta Lila Weston Institute, Institute of Neurology, UCL and National Hospital, Queen Square, London, United Kingdom | Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, London, UK | University Colle